Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Understanding the biology and therapeutic potential of RAS in frontline AML and CMML

Sandra Misale • 18 Sep 2026
Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Leukemia Azacitidine Daraxonrasib RMC-7977 Venetoclax

Sandra Misale, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, presents on the biology and therapeutic potential of RAS in frontline acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Dr Misale discusses the mechanism of action of daraxonrasib, the unmet clinical need in RAS-driven secondary AML (sAML), data on the response to RMC-7977 in RAS-mutant sAML, and the potential of combination with azacitidine. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Related Videos

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals